EUCTR2006-001973-10-NL进行中（未招募）不适用
A Phase 2 study comparing sequential satraplatin and erlotinib to single-agent erlotinib in patients >/= 70 years of age with unresectable stage 3 or 4 non-small cell lung cancer as 1st -line therapy
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically confirmed NSCLC (squamous cell carcinoma, adenocarcinoma, or large cell carcinoma). Cytologic specimens obtained by brushings, washings or needle biopsy with aspiration are acceptable. Mixed tumors with small cell anaplastic elements are not eligible.
- •Patients who have unresectable stage III or stage IV disease are eligible. Patients with stage III disease should be ineligible for combined modality therapy (i.e. pleural effusions, pericardial effusions, etc.). Patients with earlier stage NSCLC that has recurred after prior surgery are eligible.
- •Age = 70 years old.
- •ECOG performance status 0-1
- •Prior treatment with systemic therapy is allowed provided the following criteria are met:
- •- No EGFR targeted therapy (TKI or antibody)
- •- No prior platinum agent
- •- Neoadjuvant, adjuvant, or part of a combined modality regimen (i.e., not
- •for metastatic disease)
- •- Completion > 6 months prior to enrollment onto this study.
- •Patients who have had previous radiation therapy (RT) as definitive therapy for locally NSCLC are eligible only if the following criteria are met:
- •- Site of tumor recurrence is outside of the original RT port unless there is incontrovertible evidence of disease progression within the portal.
- •- All side effects from RT must have resolved prior to enrollment.
- •- Completion of RT = 4 weeks prior to enrollment.
- •- Previous radiation must have treated < 30% of active bone marrow.
- •- Patients who have undergone thoracotomy must have fully recovered from surgery and cannot start treatment until at least three weeks after their operative procedure.
- •Adequate hematological function as noted by:
- •- Absolute neutrophil count (ANC) > 1,500/uL
- •- Platelets > 100,000/uL
- •- Hemoglobin > 10 g/dl. Patients may be transfused or receive erythropoietin to maintain or exceed this level.
- •Adequate hepatic and renal function as noted by:
- •- Bilirubin < 1. 5 x upper limit of normal (ULN)
- •- Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) <2.5 x ULN.
- •- Serum creatinine <1.5mg/dL or calculated (or measured) glomerular filtration rate (GFR) = 50 ml/min.
- •Life expectancy of at least 3 months.
- •Patients with both measurable and non-measurable disease (as per Response Criteria in Solid Tumors (RECIST)) may be enrolled.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Concurrent invasive malignancy requiring ongoing therapy
- •Metastatic brain or meningeal tumors unless the patient is > 1 month from definitive therapy, is clinically stable with respect to the tumor at the time of study entry, is not receiving steroid therapy or taper, and is not receiving anti-convulsant medications (that were started for the brain metastases)
- •Previous treatment with either platinum-based chemotherapy agents or prior EGFR targeting agents.
- •Peripheral neuropathy > grade 1.
- •Hearing loss or tinnitus > grade 2
- •Obstructive pulmonary disease or symptoms > grade 3.
- •A history of cardiac disease as defined by malignant hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous six months, or symptomatic uncontrolled cardiac arrhythmias.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 Study comparing sequential satraplatin and erlotinib to single-agent erlotinib in patients >70 years of age with unresectable stage 3 or 4 Non-small Cell Lung Cancer as 1st-line therapy - satraplatin+erlotinib NSCLC pts > 70 yrs 1st linePatients > 70 years of age with locally advanced or unresectable stage III-IV NSCLC, with no prior sistemic treatment for metastatic disease.MedDRA version: 9.1Level: LLTClassification code 10059515Term: Non-small cell lung cancer metastaticEUCTR2006-001973-10-ITGPC BIOTECH120
未知
1 期
Phase I Study of Satraplatin Plus PrednisoloneJPRN-jRCT2080220611Yakult Honsha Co.,Ltd.6
已完成
2 期
A phase II study of S-1 plus cisplatin with concurrent radiation for locally advanced thymic carcinoma (LOGIK1605/JART-1501)Thymic carcinomaJPRN-UMIN000024643Clinical Research Support Center Kyushu30
招募中
2 期
A Phase II Study of Carboplatin and S-1 Followed by S-1 Maintenance for Patients Who Have Squamous Cell Lung CarcinomaSquamous Cell Lung CarcinomaJPRN-UMIN000007433Central Japan Lung Study Group (CJLSG)30
尚未招募
1 期
Phase I/II Trial of S-1 and Nedaplatin with concurrent radiotherapy in locally advanced mesopharynx, hypopharynx cancerMesopharyngeal cancer Hypopharyngeal CancerJPRN-UMIN000003889Kitasato University School of Medicine43